Connectome Secures €1.7 Million to Scale Personalized Brain Health Insights and Early Cognitive Change Detection

In a groundbreaking move for the NeuroTech industry, Zurich and London-based startup Connectome has successfully closed a pre-Seed financing round of €1.7 million ($2 million). This funding aims to revolutionize how we interpret brain health by providing measurable, personalized insights into cognitive function.

The Funding Round and Vision

Led by Redstone, this round saw participation from prominent early-stage venture funds such as Concept Ventures and Octopus. The funding mix includes €103.6k ($120k) in non-dilutive public innovation funding, complementing private venture capital. Connectome's ambitious vision is to bridge the gap in understanding brain health, which has not advanced as rapidly as physical health metrics.

Lucas Scherdel, CEO of Connectome, emphasizes the urgency of their mission, noting, “Cognitive capacity underpins how we think, work, relate, and age, yet it remains poorly understood. Our environments and technologies now place unprecedented demands on the brain, but we lack everyday ways to detect early change or protect long-term cognitive health.”

Founders and Scientific Foundation

Founded in 2024 by Lucas Scherdel and Dr. Rufus Mitchell-Heggs, Connectome is poised to make significant strides in the field of neuroscience. Scherdel, with a background in global R&D and experience at the World Health Organization, brings a wealth of knowledge to the company. Meanwhile, Dr. Mitchell-Heggs, a computational neuroscientist, will spearhead the development of neural biomarkers, building on his research in memory and social cognition.

The startup's technology is rooted in research conducted with Imperial College London. Their LUCID study has shown that everyday behavior leaves a measurable signature in brain activity, offering new ways to monitor and enhance cognitive function.

Transforming Cognitive Health

Connectome's approach could be transformative for conditions like ADHD and dementia, enabling earlier detection of cognitive changes. Traditional methods rely on static snapshots, but Connectome personalizes brain measurement by monitoring activity multiple times over a period. By integrating this data with lifestyle factors such as sleep and activity, the company provides a comprehensive view of cognitive health.

Dr. Mitchell-Heggs explains, “The LUCID study is designed to begin characterizing the healthy ‘neighborhood’ of brain activity. When neurological issues arise, patterns can drift from this zone. By measuring repeatedly, we can understand these shifts and map conditions or risk profiles, making brain health assessment more objective and actionable.”

Implications for Startups and Investors

For startups and investors, Connectome's journey highlights the potential of merging technology with healthcare to address unmet needs. The focus on cognitive health taps into a growing market as mental well-being becomes increasingly prioritized. The strategic investments and strong scientific foundation position Connectome as a leader in NeuroTech, offering valuable insights for those looking to innovate in health tech.

Conclusion

With this substantial funding, Connectome is set to launch its product with select partners and explore new applications beyond lifestyle and wearables. Their pioneering work in personalized brain health could redefine how we approach cognitive well-being, making significant impacts across healthcare and technology sectors.

Source: EU-Startups